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Topics in Type 2 Diabetes and Insulin
Resistance
ZACHARY T. BLOOMGARDEN, MD
T
his is the second of six articles based
on presentations at the American
Diabetes Association Scientiﬁc Ses-
sions held 6–10 June 2008 in San Fran-
cisco, California.
Predicting diabetes
Frederick Brancati (Baltimore, MD) dis-
cussed diabetes screening. Approaches
usingage,sex,BMI,familyhistory,hyper-
tension, and lifestyle as predictive mea-
sures have shown good performance in
cross-sectional and prospective studies,
and capillary glucose measurement adds
further value, although the public health
impact of such approaches has not been
determined. In the Diabetes Prevention
Program (DPP), 158,177 individuals
were screened, with 3,819 randomized.
Thosewhosefastingcapillaryglucosewas
90–115 mg/dl had increased risk of im-
paired glucose tolerance (IGT); levels
130 mg/dl were 250 times as likely as
levels 90 mg/dl to be associated with
IGT. Patrick O’Connor (Minneapolis,
MN) pointed out that health plans have
become very interested in identifying and
treating diabetes and addressed the ques-
tion of whether systematic identiﬁcation
of pre-diabetes by screening leads to bet-
ter health outcomes than would occur
without screening. Developing an ap-
proach to identiﬁcation and subsequent
interventions that would be cost-effective
is an important priority. O’Connor re-
viewed responses to a survey of medical
directors of 35 plans, caring for a total of
47 million individuals, focused on aware-
ness of cardiometabolic risk. At-risk en-
rollees can be identiﬁed by age, BMI, sex,
race, laboratory test results, physician di-
agnoses, smoking history, and prescrip-
tion data based on pharmacy claims,
although lack of electronic medical
recordsis“aweaklink.”Durationoftreat-
ment and of illnesses (including diabetes)
and other aspects of medical history are
not readily available.
Nonetheless, using all the available
information, it certainly is possible to
identify individuals at increased diabetes
risk. Two approaches are taken: 1) direct
outreach to large numbers of people for
prevention of adverse outcome or 2) case
management of smaller numbers of peo-
ple at much higher risk. In large-group
outreach approaches, smoking cessation,
healthy eating, and physical activity are
typically recommended and the impor-
tanceoflipidandbloodpressuremanage-
ment is emphasized, but glucose
measurement and approaches to reduc-
tion of glucose intolerance and insulin re-
sistance are not currently recommended
by the majority of managed-care pro-
grams. In disease management ap-
proaches, measures to improve insulin
sensitivity and glycemia are limited to
management of individuals with existing
diabetes. Cardiometabolic risk informa-
tion is, however, being given to partici-
pants in many plans, with priorities for
health coaching, health risk appraisal,
and incentives, such as discounts on
health club membership. Use of case
managementtooverseetreatmentplansis
lessfrequentlybeingpursuedthanwhatis
termed the “medical home” primary care
approach of treatment managed and co-
ordinated by an individual physician.
Health care providers are offered lipid,
blood pressure, and preventative health
service guidelines, but the American Dia-
betes Association (ADA) guidelines are
not typically stressed, and O’Connor sug-
gested that “guidelines are increasingly
being viewed as irrelevant.” Rather, “pay-
ment for performance” initiatives are
more “front and center,” he said, and as-
sistance in coordination of care infre-
quently addresses pre-diabetes. Medical
directors feel that they do not have sufﬁ-
cient resources for such efforts and be-
lieve that “there is an evidence problem”
and are hampered by limited information
systems, although O’Conor suggested
that once diabetes is diagnosed, obesity,
A1C, blood pressure, LDL cholesterol,
andaspirinuseallimprove,“sowhenyou
activatethesesystems...youcangetalot
done.” A missing tool is the electronic
medical record, which could be readily
used to identify individuals at high risk
and could incorporate linked patient
“portals” or proactive “e-visits,” for which
providers could be offered reimburse-
ment, and either simple alerts or more
complex decision-support tools to allow
physician-directed interventions. The
surveyed health plan directors indicated
that complicated screening tests (which
they apparently consider to include glu-
cose tolerance testing) are less likely to be
used.
Paul Franks (Umeå, Sweden) dis-
cussed genetic aspects of diabetes risk
prediction, particularly “context-
dependent genetic effects” that may be
used to enhance risk prediction. He con-
trasted genetic and familial risk, the
former representing the disease risk at-
tributabletocarryingoneortwocopiesof
a speciﬁc risk allele. These include poly-
morphisms of KCNJ11 (controlling the
-cell ATP-sensitive K
 channel) (1),
PPAR (2), and TFC7L2 (3), although he
noted that candidate gene approaches are
less efﬁcient than genome-scanning ap-
proaches in ﬁnding gene associations,
with nearly 20 validated genetic risk fac-
torshavingbeendiscovered,forexample,
in the Data from an Epidemiological
StudyontheInsulinResistancesyndrome
(DESIR) study (4). In contrast, familial
risk is the disease risk shared between bi-
ological relatives, but family members
share behaviors as well and exposure to
diabetes in utero is another potential fac-
tor. Using receiver-operating curve
(ROC) analysis, family history gives a
fairly modest ROC area of 0.57 and ge-
netic markers are somewhat better with
ROC area 0.63, but the combination of
familyhistoryandclinicalpredictorsfrom
the Framingham score gives an ROC area
of 0.88 (a powerful predictor), whereas
adding genetic information in a Swedish
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ditional information. Thus, such an ap-
proach may not yet be useful.
An alternative is the use of context-
dependent genetic risk markers depen-
dent on the level of environmental
exposure: the use of genetic information
in the context of speciﬁc environmental
factors. In the DPP, 3,548 participants
weregenotyped.Metforminandintensive
lifestyle decreased risk by 32 and 58%,
respectively, with 90% reduction in dia-
betes among those adhering most
strongly to lifestyle recommendations.
The transcription factor 7–like 2 gene
(TCF7L2) is the strongest single genetic
risk factor for type 2 diabetes (5). In the
DPP, the TCF7L2 genotype predicted
progression to diabetes in the control
group,withthosehavingtheTTgenotype
at rs7903146 at greater risk of decreas-
ing insulin secretion while those in the
lifestyle intervention group had no in-
creased diabetes risk with the variant
genotype, which can be considered an
example of context-speciﬁc risk. Perox-
isome proliferator–activated receptor 
(the target of thiazolidniediones, whose
natural ligands are polyunsaturated
fatty acids) displays PPARG2 polymor-
phisms, with the ala-ala genotype asso-
ciated with lower and the pro-pro with
higher BMI and the environmental inter-
action being with dietary fat. Both
PPARG2 and KCNJ11 E23K polymor-
phisms affected response to various DPP
interventions. In assessing genomic anal-
ysis one needs to consider analytic and
clinical validity, the ability of such testing
to detect or predict diseases, and clinical
utility when compared with existing
screening approaches (6). There is a po-
tential for both beneﬁt and adverse con-
sequenceofsuchinformation,butFranks
predicted that ultimately genetic screen-
ingwillallowunderstandingoftheriskof
not only diabetes but a great variety of
additional clinical conditions.
A number of studies presented at the
ADA meeting addressed aspects of the ge-
netics of type 2 diabetes. Frayling et al.
(abstract 936) noted that sex hormone–
binding globulin (SHBG) levels are re-
duced in individuals with insulin
resistance and individuals with type 2 di-
abetes,ﬁndingamong1,200individualsa
variant allele of SHBG with frequency
0.31 associated with higher SHBG levels
and 9% reduction in likelihood of diabe-
tes, which suggests that the direction of
causality may be from SHBG to diabetes
rather than (as is usually assumed) an ef-
fect of reduced insulin sensitivity in low-
ering SHBG levels. Foo et al. (abstract
985)reportedanalysisof135nondiabetic
men who requested evaluation for sexual
dysfunction; fasting glucose showed neg-
ative correlation with testosterone and
SHBG, the latter a signiﬁcant predictor in
multivariate analysis. (Abstract numbers
refer to the ADA Scientiﬁc Sessions, Dia-
betes 57 [Suppl. 2], 2008).
Many other polymorphisms were re-
ported to be associated with diabetes, in-
cluding those of SLC24A3, an Na/K/Ca
exchanger (NCKX3) highly expressed in
skeletal muscle and brain (Powers et al.,
abstract314);kalirin,alsoassociatedwith
atherosclerosis and metabolic syndrome
(Rudock et al., abstract 140); BQ231042,
of unknown function, expressed in brain,
islet, liver, kidney, adrenal, thyroid and
skeletal muscle (Zhang et al., abstract
138); a cluster spanning genes for glu-
cose-6-phosphatase catalytic unit two
and ATP-binding cassette, sub-family B
(MDR/TAP), member 11 and a neuronal
cell surface protein, neuroligin one (Wa-
tanabe et al., abstract 137); the vesicle
transportsolubleNSFattachmentprotein
receptor vps10p tail interacting 1a gene,
located on chromosome 10q, which also
contains the TCF7L2 gene (Lehman et al.,
abstract 136); the mannan-binding lec-
tin-2 gene, encoding an important com-
ponent of the innate immune system
(Muller et al., abstract 135); the JAZF1,
CDC123/CAMK1D, ADAMTS9, and
THADA gene regions (Saxena et al., ab-
stract 134); the CDKAL1 and HHEX-IDE
genes, in part mediating the association
between low birth weight and diabetes
(Freahy et al., abstract 133); the PPAR
coactivator 1 gene (Arya et al., abstract
1815);TCF7L2andHHEXgenes(Horiko-
shi et al., abstract 1181; Shang et al., ab-
stract 274; and Chang et al., abstracts
1168); the Lim domain homeobox gene,
encoding a transcription factor involved
in pancreatic development (Muller et al.,
abstract 1180); the perilipin gene, in-
volved in regulation of adipocyte lipid
storage (Li et al., abstract 1178); the adi-
ponectin gene (Hivert et al., abstract
1178); the nuclear factor B inhibitor-
gene (Miller et al., abstract 1176); the in-
terleukin-18 gene (Presta et al., abstract
1170);theLass6geneencodingamember
of the longevity-assurance homologue
family(Goodetal.,abstract1167);ascav-
enger receptor class B type 1 gene (An et
al., abstract 1166); the TRIB3 gene inhib-
itinginsulin-stimulatedAktphosphoryla-
tion (Prudente et al., abstract 1165); and
some 27 further studies of genes covering
the entire gamut of factors related to gly-
cemia.Clearly,thisisanimportantareaof
investigation likely to lead to new under-
standing of the pathogenesis of diabetes
and the development of new therapeutic
approaches.
William Knowler (Phoenix, AZ) dis-
cussed the importance of detecting im-
paired fasting glucose (IFG) and IGT. At
fasting and 2-h glucose levels above 125
and 228 mg/dl, respectively, and at A1C
above 6.6%, the prevalence of diabetic
retinopathy in a study of 5,007 Pima In-
dians increased from negligible levels to
12% (7,8). Analysis of 1,133 incident
cases of diabetes in 31,563 person-years
of follow-up of initially nondiabetic Pima
Indians 20 years ago showed that as
fasting glucose increased from 95 to
95–104, 105–109, and 110–125 mg/dl,
the rate of subsequent development of di-
abetes increased from 20 to 40, 80,
and 120 cases/1,000 person-years, re-
spectively. Analysis of the population
based on A1C showed that levels 5.5,
5.5–5.9, 6–6.4 and 6.5% were associ-
ated with diabetes rates of 20, 50,
120, and 340 cases/1,000 person-years,
respectively. IFG and IGT can exist either
separately or in combination and have
been termed pre-diabetes, but Knowler
pointedoutthattheglucosetolerancetest
is not highly reproducible, with fewer
than half of individuals having IGT in the
Hoorn study showing IGT on a second
test 2–6 weeks later (9). Nevertheless,
among Pima Indians, those with either
IFG or IGT alone had a threefold increase
andthosewithbothhadaseven-toeight-
fold increase in diabetes development.
Knowler recommended that similar clas-
siﬁcations be based on A1C given its pre-
dictive power and clinical utility.
There is good evidence that diabetes
can be prevented by treatment of IFG/
IGT. A 12-month period of 750 mg met-
formin daily versus placebo in 70
individuals having IGT on two consecu-
tive tests led to reductions in both fasting
and 2-h glucose levels (10), and the Da
Qing Clinical Trial of lifestyle interven-
tionwithdiet,exercise,both,orneitherin
530 IGT patients reduced diabetes devel-
opment over 6 years from 68 to 40%
(11). In the DPP, carried out from 1996–
2001, diabetes incidence rates among
high-risk individuals with IGT were 11,
7.8,and4.8%peryearwithplacebo,met-
formin, and an intensive lifestyle inter-
vention, respectively (12). There is
evidence of increased cardiovascular risk
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(14), studies show increased risk with
IFG.TakingintoaccountCVDriskfactors
may reduce the excess risk associated
with pre-diabetes (15,16). Part of the dif-
ﬁculty in associating pre-diabetes with
risk may be that only a subset of these
individuals progress to diabetes, with ev-
idencethatadverseeffectsarerestrictedto
those individuals who progress to devel-
opment of diabetes shown in studies in
the Netherlands (17) and among Pimas
(18). Interestingly, A1C may be a more
powerful risk factor than glucose, with
analysis of the European Prospective In-
vestigation of Cancer (EPIC)-Norfolk
studyshowingadoublingofCVDmortal-
ity among individuals with A1C 5–5.4%
or 5.5–6.9% compared with that among
individuals with A1C 5% (19).
StephenColagiuri(Sydney,Australia)
discussedthequestionofwhetherthereis
value in early detection of diabetes and of
pre-diabetes in terms of individual out-
comes and from a health system perspec-
tive. There is a hierarchy: from
nondiabetic patients at lower versus
higher risk to undiagnosed diabetes and
then to diagnosed diabetes. Although mi-
crovascular risk has been thought to be-
gin with the onset of diabetes, this is now
being reconsidered, and macrovascular
risk does precede diabetes onset. Im-
provement in both micro- and macrovas-
cular outcomes is certainly achievable.
Colagiurireviewedtheasyetindirectdata
suggesting beneﬁt of preventing or delay-
ing diabetes, beginning by mentioning
the many studies showing beneﬁt of life-
style and of a variety of pharmacologic
approachesinreducingdiabetesdevelop-
ment. Analysis of the small Malmo ¨hus
Prevention trial of 147 pre-diabetic indi-
viduals showed a trend to lower cardio-
vascular mortality with tolbutamide
treatment (20). The Diabetes REduction
Assessment with ramipril and rosiglita-
zone Medication (DREAM) study showed
reduction in a composite renal outcome
with rosiglitazone (21). In the STOP-
NIDDM study, acarbose treatment was
associated with a reduction in myocardial
infarction (22). The 20-year follow-up
of the Da Qing lifestyle intervention
showed a signiﬁcant 40% reduction in
incident diabetes and, although under-
powered with fewer than 600 partici-
pants, did show a trend of lower CVD
mortality (23).
Undiagnosed diabetes is certainly
common, comprising 30–80% of dia-
betic individuals, depending on the pop-
ulation studied, and may be lengthy in
duration and associated with risk of de-
veloping complications and premature
mortality. There is no evidence that dia-
betes detection improves outcome. The
Anglo-Danish-Dutch Study of Intensive
TreatmentinPeoplewithScreenDetected
Diabetes in Primary Care (ADDITION)
assessed the risk of 400,000 individuals,
of whom 76,000 had been recommended
for an examination, and recruited 3,000
previously undiagnosed diabetic individ-
uals to participate in a multifactorial in-
tensive treatment versus standard
treatment (24). Of this group, 72% have
bloodpressure140/90mmHg,58%are
not receiving antihypertensive treatment,
mean A1C is 7%, and 70% have hyper-
cholesterolemia, for which 90% are not
receiving treatment. Results will be pre-
sented in 2009, although the study is un-
derpowered to ascertain cardiovascular
beneﬁt. Colagiuri described several case-
control studies based on a glycosuria
screening of 300–500 individuals with a
suggestionofbeneﬁtoftreatment,though
again with an inadequate sample size. In-
terestingly,analysisofUKProspectiveDi-
abetes Study participants by fasting
glucose at presentation indicates that
thosewithlevels7.8–10and10mmol/l
had diabetes for 2–3 and 5 years longer,
respectively, than those with fasting glu-
cose 7.8 mmol/l. All end points oc-
curred more often in the group with
higher fasting glucose, and diabetes-
related death and myocardial infarction
were more common in the intermediate
than in the low fasting glucose group;
thus, given the appropriate patient popu-
lation, early treatment might well be ef-
fective (25).
Health system value depends on both
cost and cost-effectiveness. Diabetes
screening is not particularly expensive.
Colagiuri reviewed an Australian study
ﬁnding a cost of approximately 746 USD
per case. Information on outcome is
needed, however, to calculate cost-
effectiveness. Modeling, relying on as-
sumptions as to long-term beneﬁt, does
suggest that an intervention such as that
of the Diabetes Prevetnion Program
would be cost-effective (26). An interest-
ing cost-effectiveness modeling study of
diabetes screening and prevention pro-
grams suggested that screening for diabe-
tes alone is not as cost-effective as
screening for pre-diabetes as well with ei-
therlifestyleorpharmacologicalinterven-
tions (27). We need to appropriately
prioritize such efforts and to develop ca-
pacity and resources to care for undiag-
nosed diabetes and, perhaps, for pre-
diabetes as well. “Events are overtaking
us,” Colagiuri concluded, with programs
being developed in Finland and Australia
and the Diabetes in Europe–Prevention
using Lifestyle, physical Activity and Nu-
tritional intervention (DE-PLAN) project
in progress.
A number of studies presented at the
ADAmeetingfurtheraddressedaspectsof
pre-diabetes. Oza-Frank and Narayan
(abstract 316) studied diabetes develop-
mentintheU.S.foreign-bornpopulation.
There are currently more than 35 million
such individuals, with immigrants from
the Indian subcontinent having the high-
estdiabetesrisk:3.3-foldgreaterthanthat
of those born in the U.S., adjusted for
BMI, age, sex, poverty income ratio, and
duration of residence. Imperatore et al.
(abstract 26) analyzed cardiometabolic
risk factors in adults age 20–44 years in
the U.S. from 1988–1991, 1991–194,
1999–2002, and 2003–2004, showing
that the prevalence of obesity increased
from 19 to 31%, mean waist circumfer-
ence increased from 89 to 94 cm, and di-
abetes prevalence increased from 0.5 to
1.5%betweenages20and34years,with-
out change from ages 35–44 years (de-
creasing from 2.5 to 2.4%). Fasting
glucose 100 but 126 mg/dl increased
from 20 to 24% in 20- to 34 year olds but
declined from 22 to 15% in 35-to 44 year
olds. Mean A1C levels increased 0.14%
for 20- to 34 year olds and 0.08% for 35-
to 44 year olds, and mean fasting insulin
rose from 9 to 13 and from 11 to 13
	U/ml in the respective groups. Triglyc-
erides increased 15 mg/dl in those aged
20–34 years. LDL cholesterol, blood
pressure, and smoking failed to change
during this period. Vella et al. (abstract
318)compared329individualswithcog-
nitive impairment with 1,640 control
subjects and found the former to have a
lower prevalence of a cyclin-dependent
kinase CKN2A/B polymorphism, also as-
sociated with diabetes and with vascular
disease, which is of potential importance
given evidence that dementia may be asso-
ciated with insulin resistance. Scheen et al.
(abstract 319) found metabolic syndrome
byAdultTreatmentPanelIIIcriteriain23%
of 112 patients with bipolar disorder, 29%
of 503 with schizophrenia, and 50% of 92
with schizoaffective disorder. Diabetes was
present in 8%, and 22% had either im-
paired fasting glucose or impaired glucose
tolerance. Differences between the condi-
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tions and other factors.
Aspects of pre-diabetes in the pediat-
ric population were also addressed in
studies presented at the ADA. Sathasivam
et al. (abstract 1774) analyzed character-
istics of 88 obese youth, noting that those
with fasting glucose 90–99 mg/dl had
fastinginsulin,homeostasismodelassess-
ment of insulin resistance (HOMA-IR),
and triglycerides similar to those with
fasting glucose 100–125 mg/dl, which
suggests that the cutoff of 100 mg/dl may
be appropriate for adults but not for chil-
dren. Libman et al. (abstract 1779) per-
formed two oral glucose tolerance tests in
60 overweight youth 5 days apart. Of 10
subjects with IGT, 7 normalized in the
second test, and the correlation coefﬁ-
cient between fasting glucose levels was
0.73,exceedingthatfor2-hglucoselevels
(0.37). One may speculate that in addi-
tion to inherent lack of reproducibility,
there was a behavioral change between
the two tests leading to improvement on
retesting. Pettitt et al. (abstract 30) com-
pared age of onset of type 2 and type 1
diabetic individuals exposed to maternal
gestational diabetes mellitus in utero
basedondatafromtheSEARCHstudy.Of
the diabetic patients aged 20 years, 111
with type 1 and 113 with type 2 diabetes
also had mothers with diabetes—88 dur-
ing gestation. Age at onset of type 1 dia-
betes was not signiﬁcantly earlier with
maternal diabetes before pregnancy, but
type 2 diabetes occurred at an earlier age
inassociationwithmaternaldiabetesdur-
ing the pregnancy, suggesting an adverse
effectofthediabeticintrauterineenviron-
ment. Lawrence et al. (abstract 25) de-
scribed data from the SEARCH study
pertaining to type 1 and type 2 diabetes
incidence and prevalence among U.S.
Hispanic Youth. Peak type 1 diabetes
incidence was 20 per 100,000 for fe-
male subjects at age 5–9 years and 20
per 100,000 for male subjects at age
10–14 years, with type 1 rather than
type2diabetesthemostprevalentform.
Vehik et al. (abstract 963) measured in-
tramyocellular lipids using soleus mus-
cle 1H-nuclear magnetic resonance
spectroscopy in 67 children, age 8–12
years, and found levels to be similar in
overweight/obese and nonobese chil-
dren. Birth weight, however, was in-
versely proportional to muscle fat, with
the highest levels among children in the
lowest birth weight tertile who cur-
rently were overweight or obese, sug-
gesting an in utero component to
insulin resistance.
Nonalcoholic fatty liver disease
There is increasing interest in the interre-
lationships between pre-diabetes, insulin
resistance, and liver fat. Cali et al. (ab-
stract 33) found that 30, 25, and 67 of
122 obese adolescents had 15, 5–15,
and 5% hepatic fat on magnetic reso-
nance imaging (MRI), respectively, with
higher liver fat associated with higher vis-
ceral fat, 2-h glucose, and fasting and
postchallenge insulin levels. Saremi et al.
(abstract 1009) measured liver fat on
computerized tomography in 281 type 2
diabetic individuals, ﬁnding higher liver
fat in younger patients with shorter dia-
betes duration in association with higher
triglyceride and C-reactive protein and
lower HDL cholesterol and adiponectin
levels. Saluja et al. (abstract 657) found
that75%of1,079type2diabeticpatients
in their clinic in India had ultrasound ev-
idence of hepatic steatosis, with 34% of
this group vs. 19% of those without liver
abnormality having coronary artery dis-
ease and 16 vs. 7%, respectively, having
cerebrovascular disease. However, Her-
mans et al. (abstracts 640 and 649) failed
to show a relationship between ultra-
sound hepatic abnormalities or upper
-glutamyl transferase (GGT) quintile
and cardiovascular disease among 488
patients having GGT measurement and
258 having sonography in Belgium, with
24 vs. 26% having CAD and 7% vs. 8%
havingcerebrovasculardisease.Guoetal.
(abstract959)reportedthatfourgenesas-
sociated with insulin resistance (adi-
ponectin structural gene; ectonucleotide
pyrophosphatase/phosphodiesterase 1;
growth factor receptor-bound protein 2;
and protein tyrosine phosphatase, nonre-
ceptor type 1) were also associated with
liverenzymeabnormalitiesamongnondi-
abetic individuals in a survey of 1,800
participantsintheInsulinResistanceAth-
erosclerosis Study. Rhee et al. (abstract
1015) followed 15,250 Korean men from
2002 to 2006, with those in the second,
third,andfourthage-adjustedquartilesof
serum GGT having 1.9 and 1.5-fold, 3.4
and 2.8-fold, and 5.5 and 7.2-fold in-
crease in risk of developing metabolic
syndrome by the International Diabetes
Federation and Adult Treatment Panel III
criteria, respectively. GGT was also asso-
ciated with risk for metabolic syndrome
components, and alanine aminotransfer-
ase was similarly associated with in-
creased risk.
Several studies addressed therapeutic
approaches. Tsuchiya (abstract 516) ran-
domized 34 individuals with impaired
glucose tolerance and 27 with diabetes
and nonalcoholic fatty liver disease to 12
weeks of treatment with nateglinide, vo-
glibose, or pioglitazone. Liver fat by com-
puted tomography, inversely related to
density in Housnﬁeld units, increased
from 51 to 58 with nateglinide and from
50 to 58 with pioglitazone while not
changing with voglibose, suggesting that
-glucosidase inhibitors should be con-
sidered; adiponectin increased and vis-
ceralfatandliverenzymelevelsdecreased
only with pioglitazone. Kantartzis et al.
(abstract 34) studied 170 nonalcoholic
individuals with increased diabetes and
CVD risk having a 9-month lifestyle in-
tervention, which was associated with
reduction in total, subcutaneous ab-
dominal, visceral, and, to the greatest
extent, hepatic fat on MRI. High ﬁtness
at baseline strongly predicted the de-
crease in liver fat. Milner et al. (abstract
67) found reduced insulin sensitivity in
30 men with hepatitis C, appearing to
reﬂect abnormal muscle glucose up-
take. Hepatic fat content measured by
MRI was increased in genotype 3, but
not with the genotype 1 virus, and was




relates of HOMA-IR among 3,692 nondi-
abetic adults from the National Health
andNutritionExaminationSurvey1999–
2004; for those in the highest tertile of
HOMA-IR, the prevalence of low HDL
cholesterol was greater than that of high
triglycerides, particularly among non-
Hispanic blacks. Homeostasis model as-
sessment may not, however, be a reliable
measure of insulin sensitivity. Munoz et
al. (abstract 1013) compared HOMA-IR
with glucose disposal rate measured by
hyperinsulinemic-euglycemic clamp in
65 pairs of sex- and insulin sensitivity–
matched blacks and whites, ﬁnding the
square of the correlation coefﬁcient (a
measure of the fraction of variance ex-
plained by the relationship) to be only
0.14 among blacks and 0.25 among
whites. In the middle and highest clamp
insulin sensitivity tertiles, HOMA-IR was
53–54% higher in blacks than in whites,
suggesting that it should not be used
when individuals from different ethnic
groups are studied (and may have limited
Perspectives on the News
e16 DIABETES CARE, VOLUME 32, NUMBER 2, FEBRUARY 2009utility in general, given the low correla-
tion with true insulin sensitivity). Similarly,
Shaibi et al. (abstract 234) compared
changesininsulinsensitivityusingHOMA-
IR, frequently sampled intravenous glucose
tolerance test, and clamp insulin sensitiv-
ity and found that neither with a 16-week
exercise intervention nor with a 12-week
dietary intervention in adolescents did
HOMA-IR show signiﬁcant improve-
ment, despite improvements in the other
measures of insulin sensitivity. Kim and
Reaven (abstract 1298), however, noted
that insulin sensitivity, based on steady-
state plasma glucose during insulin and
glucose infusion with suppression of en-
dogenous insulin secretion in 446 non-
diabetic individuals, had a correlation
coefﬁcient of 0.76 with the integrated in-
sulin response to a 75-g oral glucose load
and with 95% of those in the highest in-
sulinresistancequartilehavinginsulinre-
sponse above the median while 92% of
those in the lowest insulin resistance
quartile had insulin response below the
median, suggesting that “insulin resis-
tanceandhyperinsulinemiararelyexistin
isolation.” Of course, this simply means
that HOMA-IR, which is roughly equiva-
lent to the fasting insulin in nondiabetic
individuals, is a good qualitative marker
ofinsulinresistance,althoughitlackssuf-
ﬁcient precision to be used quantitatively
NEWS FROM THE FOOD AND DRUG ADMINISTRATION
From time to time, new announcements by the FDA pertaining to aspects of diabetes treatment will be highlighted in this section.
In December, 2008, the FDA issued a document entitled “Guidance for Industry Diabetes Mellitus—Evaluating Cardio-
vascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes” (http://www.fda.gov/cder/guidance/8576fnl.pdf),
outlining “the Agency’s current thinking” in an effort “to ensure that relevant issues related to minimizing cardiovascular risk
are considered in ongoing drug development programs.” The document begins by acknowledging that “reliance on HbA1C
remainsanacceptableprimaryefﬁcacyendpointforapprovalofdrugsseekinganindicationtotreathyperglycemiasecondary
to diabetes mellitus.” This is an important statement. In the wake of questions regarding the cardiovascular safety of diabetes
treatment, some authors suggested that simply demonstrating that an agent improves glycemia was not adequate, asking
rather that there be “proof of health beneﬁts” for every new agent (Psaty BM, Furberg CD: Rosiglitazone and cardiovascular
risk. N Engl J Med 356:2522-2524, 2007).
The new document does, however, require that sponsors “demonstrate that [new antidiabetic] therapy will not result in an
unacceptable increase in cardiovascular risk.” The approach to be taken for such studies is given in some detail. For each new
treatment, the document requires “an independent cardiovascular endpoints committee to prospectively adjudicate, in a
blinded fashion, cardiovascular events during all phase 2 and phase 3 trials. These events should include cardiovascular
mortality, myocardial infarction, and stroke, and can include hospitalization for acute coronary syndrome, urgent revascu-
larizationprocedures,andpossiblyotherendpoints.”Further,thedocumentstatesthat“toobtainsufﬁcientendpointstoallow
ameaningfulestimateofrisk,thephase2andphase3programsshouldincludepatientsathigherriskofcardiovascularevents,
such as patients with relatively advanced disease, elderly patients, and patients with some degree of renal impairment.” The
approach to ascertainment requires that studies be carried out in such a fashion to allow meta-analysis of events occurring in
multiple different studies of an agent, including placebo-controlled monotherapy, placebo-controlled add-on therapy, and
active comparator trials. The document points out that “the controlled trials will need to last more than the typical 3 to 6
months duration to obtain enough events and to provide data on longer-term cardiovascular risk (e.g., minimum 2 years).”
Precise statistical criteria are given, and the document requires that, to earn approval, the meta-analysis must “show that the
upper bound of the two-sided 95 percent conﬁdence interval for the estimated risk ratio” is 1.3. It is instructive to consider
thenumberofpatientsandthecharacteristicsofthepatientsrequiredforsuchtrials.Individualsparticipatinginclinicaltrials
are, in general, somewhat healthier than the overall population with the given condition, with annual cardiovascular event
rates of asymptomatic diabetic patients probably well below 1%. To obtain information regarding individuals at greater risk,
therecentVeteransAffairsDiabetesTrialmightbeconsidered:20,027patientswerescreenedtoobtaininformationfor1,791
high-risk patients with mean age 60 years and diabetes duration 11.5 years and with an overall myocardial infarction, stroke,
inoperable cardiovascular disease, cardiovascular death, and coronary, peripheral artery, and cerebrovascular intervention
rate of 5.6% per year (Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN,
Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, the VADT Investigators: Glucose
control and vascular complications in veterans with type 2 disbetes. N Engl J Med. 17 December 2008 [Epub ahead of print]).
Calculation of the sample size required to distinguish a 25% greater event rate over a 2-year period (13.9% as opposed to
11.1% in the Veterans Affairs trial group) reveals that for a 0.05% type I error, with statistical power of 80%, approximately
2,200 individuals would be required in each group (http://department.obg.cuhk.edu.hk/researchsupport/Sample_size_
Comp2Prop.asp)—approximately 2.5 times the number of participants in the Veterans Affairs trial, although observed for a
shorter period of time. Individuals at lower risk could be more readily recruited. To fulﬁll the newly proposed requirements,
however,studiesofsuchpatientswouldneedtobeconsiderablylarger.Todistinguisha2.5vs.2%annualeventrate,a2-year
study would require nearly 7,000 individuals in each group. One can speculate that such studies, although of great intrinsic
interest, would be far more expensive to carry out than has been the case hitherto for registration trials of drug approval, with
the potential undesirable consequence of reducing interest on the part of the pharmaceutical industry in developing new
therapies for the treatment of diabetes.
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DeFronzo et al. (abstract 151) mea-
sured insulin response and sensitivity in
174 individuals with isolated IGT, 50
with impaired fasting glucose IFG, 428
with both, and 115 with normal glucose
tolerance (NGT) and found similar insu-
lin sensitivity in those with normal glu-
cose tolerance and and IFG. There was an
80% decrease in insulin secretion in indi-
viduals with fasting glucose between 115
and 125 mg/dl, whereas elevation in 2-h
glucose was a combined result of insulin
resistance and reduced insulin secretion.
Xiang et al. (abstract 248) followed 60
women for up to 75 months after gesta-
tional diabetes mellitus and found a pro-
gressive fall in the acute insulin response
to intravenous glucose, whereas insulin
sensitivity was low at baseline and failed
to decrease signiﬁcantly during follow-




There is a relationship between in-
ﬂammation and insulin resistance. Jo-
shipura et al. (abstract 889) analyzed
relationships between dental disease and
diabetesinthe18-yearHealthProfession-
als’ Follow-up Study of 39,964 men and
the 12 year Nurses’ Health Study of
67,394 women. Periodontitis was associ-
ated with 38 and 78% increase, and loss
of 3 vs. 0 teeth during follow-up, with
57 and 29% increase in risk of diabetes in
the respective studies. Xiao et al. (abstract
154)infusedfatemulsionplusheparinfor
48 h to six overweight and obese non-
diabetic men, reducing insulin secretion
without improvement in response to so-
dium salicylate, although salicylate in-
creased insulin secretion during the lipid
infusion.Jungetal.(abstract565)studied
effects of the short-chain fatty acid bu-
tyrate, found in dairy products and
known to inhibit histone deacetylases
such as that mediating the suppression of
PPAR function by tumor necrosis fac-
tor-. In high-fat–fed mice with versus
without butyrate supplementation,
weight gain was reduced, with a 30% de-
crease in fat mass. Insulin sensitivity in-
creased, with increased muscle and
adipose tissue glucose utilization and in-
creased insulin-mediated suppression of
hepatic glucose production. Rumberger
et al. (abstract 1384) found lipolysis to be
stimulated by incubation of adipocytes
with butyrate in a glucose-dependent
fashion, suggesting this to be evidence of
histone deacetylase inhibition. Dietary
measures to increase butyrate intake
might prove effective in diabetes and in
treatment of other insulin resistant states.
Scullyetal.(abstract306)infusedthe
erythropoietin receptor agonist
CNTO530 in a dietary obesity and diabe-
tes mouse model, reducing fasting glu-
cose from 147 to 76 mg/dl with an 83%
decrease in insulin level and increasing
the glucose infusion required for euglyce-
mia during an insulin infusion by 2.25-
fold, with increased skeletal muscle
glucose uptake; this suggests another po-
tential approach. Xu et al. (abstract 305)
administered ﬁbroblast growth factor
(FGF)-21,apeptideexpressedintheliver
under control of PPAR, to mice with
high-fat diet–induced obesity mice and
found a dose-dependent improvement in
glucose, insulin, and triglyceride levels;
reversal of fat-induced hepatosteatosis;
and weight loss without change in food
intake. Chavez et al. (abstract 110), how-
ever, measured levels of FGF-21 in 41 in-
dividuals with varying insulin sensitivity
on a euglycemic-hyperinsulinemic clamp
andfoundFGF-21tocorrelatewithworse
glucose tolerance and lower insulin sen-
sitivity, which is an association opposite
that in rodent studies; thus, the role of
FGF-21 in man remains to be fully eluci-
dated. Araneta and Barrett-Connor (ab-
stract 895), in a study of Flipino, black,
and white women, and Ley et al. (abstract
894), in a Canadian aboriginal popula-
tion,showedthatdifferencesinadiponec-
tin explain much of the differences in
development of metabolic syndrome and
intype2diabetes,pointingoutthepoten-
tial importance of this insulin-sensitizing
adipokine.
Diabetes and malignancy
Yeh et al. (abstract 265) determined the
risksofincidentcancer,cancerdeath,and
all-cause death after cancer in adults with
versus without diabetes in a cohort of
20,703 individuals without known can-
cer, 570 of whom had diabetes. Cancer
incidence rates during 17-years of fol-
low-up were 18 vs. 9/1,000 person-years
among diabetic and nondiabetic trial par-
ticipants, respectively. Overall cancer
mortality was increased 30%, with a 2.5-
to 3.0-fold increase in mortality related to
colorectal, pancreatic cancer, and esoph-
ageal cancers. Mitri et al. (abstract 955)
reported a meta-analysis of six prospec-
tive studies showing a 59% increase in
non-Hodgkin’s lymphoma in patients
with diabetes, conﬁrmed by a mean 14%
increase in 11 case-control studies. Bar-
one et al. (abstract 978) identiﬁed 16
studies allowing ascertainment of a 41%
increase in risk of death among patients
with cancer having preexisting diabetes.
Bowker et al. (abstract 264) found a 22%
lowercancermortalityindiabeticpatients
treated with metformin but 33–171% in-
creases in mortality in the lowest, middle,
and highest tertiles of insulin use.
Whether this reﬂects beneﬁt of met-
formin,adverseeffectofinsulin,ordiffer-
ence between type 2 diabetic patients
requiring the two agents cannot be de-
duced from the reported associations.
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